Taken together, our findings suggest that miR‐138, GIT1 and SEMA4C could be novel and good targets for the development of not only anti‐proliferation, but also anti‐EMT strategies in the treatment of NSCLC. Here, GIT1 is linked to non-small cell lung carcinoma.